report describes a kindred containing two additional individuals who are homozygous for the "silent" gene. Study of these patients and their relatives provided further data of the genetics of the silent gene. New data are presented to suggest that in such rare homozygotes no significant amount of antigenically related cross-reacting material is produced.
Methods
Case reports Case 1. Patient G. Cl. (11-1; Figure 1 ) a 53-yearold white male of Irish origin was hospitalized in 1958 for elective repair of a ventral hernia. His parents were not related. Past history revealed hypertension of 3 years' duration, auricular fibrillation, and digitalis therapy for 2 years. Physical examination revealed an obese white male with a blood pressure of 180/110, moderate cardiomegaly, and a grade one apical systolic murmur. Aside from a ventral hernia, no other abnormality was noted.
Laboratory studies showed a hemoglobin of 16.4 g per 100 ml, hematocrit 50%, and leukocytes 6,600 with normal differential count. Urinalysis was normal. Nonprotein nitrogen was 25 mg per 100 ml, and cholesterol was 320 mg per 100 ml. The electrocardiogram showed auricular fibrillation and suggested left ventricular hypertrophy.
Anesthesia preparatory to the hernia repair was induced with intravenous sodium pentothal. Cyclopropane was followed by nitrous oxide, ether, and oxygen. A total of 235 mg of succinylcholine was given intravenously. Muscle 
Iiiinunnoelectrophoresis
With a method similar to that described by Grabar (18) and staining techniques described by Uriel (19) , immunoelectrophoresis of normal serum was carried out on 31-X 4-inch photographic glass plates, employing 1% Ionagar dissolved in 0.1 M barbital buffer, pH 8.6. After electrophoresis, the linear troughs were first filled with 100 IAI of normal serum in dilutions of 1: 4 to 1: 64. When this diluted serum had diffused into the agar, the troughs were charged with 100 IAl of antihuman pseudocholinesterase rabbit serum diluted 1: 8, and the plates were incubated at 40 C for 72 hours. Washing in two changes of phosphate buffer pH 7.1 during a 48-hour period was followed by staining for esterase as described above. When the antipseudocholinesterase antibodies had been neutralized by the previously added human serum, no enzyme activity was 
Results

Pseudocholinesterase levels
The mean serum esterase activity of 142 apparently normal random blood bank donors was 226 U with a SD of ± 53, as shown in Figure 2 . Esterase levels determined on the family members are indicated in Figure 1 . All members of the kindred had normal dibucaine and fluoride numbers. The index cases II-1 and II-2 had no detectable pseudocholinesterase activity and were therefore considered homozygotes for the "silent" gene. Their five children, III-1 through III- deviating by more than 2 SD from the normal mean. Other family members, II-2, 11-4, and III-6, had esterase activities below 2 SD of the mean of normals and undoubtedly were also heterozygotes for the "silent" gene.
Effect of mixing serum specimens
In order to determine whether the sera lacking any enzyme activity might contain an inhibitor substance, mixtures of enzyme-deficient serum with normal serum were prepared in the proportions indicated in Figure 3 . Absence of an inhibitor is demonstrated by the linear decrease in esterase activity that followed a curve expected from dilution alone. Fluoride and dibucaine numbers were similarly unaffected.
Starch gel electrophoretic pattern As previously described by Harris and his co-workers (16), DFP (diisopropyl fluorophosphate) inhibitable cholinesterase activity of normal serum appeared in one major and three minor zones on starch gel (Figure 4 ). Essentially identical patterns were obtained with the commercial pseudocholinesterase preparation as well as with the sera of individuals homozygous and heterozygous for the dibucaine-resistant type of enzyme variant. None of these bands was demonstrable in the sera of the two subjects homozygous for the "silent" gene. Three additional zones of esterase activity, previously described by Uriel (19) and Harris and his coworkers (16) (12) . Since that organ is the site of pseudocholinesterase production, the total lack of enzyme in individuals homozygous for the silent allele is confirmed. The enzyme is therefore completely dispensable, and its normal physiological role, if any, can be compensated by other systems.
Two variants of pseudocholinesterase (the dibucaine and the fluoride-resistant enzyme) have been previously well characterized (4) and their heredity studied. Family data fit the hypothesis that both variants are determined by mutant genes (Ela and El') allelic to the gene determining the normal enzyme (Elu) (4, 6, 23, 24) . Table I presents all of the known phenotypes and genotypes of the pseudocholinesterase system along with their associated laboratory findings and population frequencies. Individuals sensitive to suxamethonium are either homozygous or mixed heterozygous for the mutant genes E1R and Elf or the "silent" gene. All presently available pedigree data and considerations based on population genetics suggest that the "silent" gene is an allele of the normal esterase gene and its two allelic mutants (8, 9, 11, 23) . The kindred presented here provides further evidence against the alternative hypothesis (8) (25, 26) .
In studies on human subjects, no CRM was detected in muscle phosphorylase deficiency (27) and in the Japanese type of acatalasemia (28, 29 A variety of genetic mechanisms could lead to the present findings. Considering that the silent gene mutation is allelic, an operator negative mutation (32) (33) (34) at the pseudocholinesterase locus is an attractive hypothesis. However, at the present time, proof for this type of mutation does not exist yet in mammalian systems.
Structural gene mutation affecting directly or indirectly both antigenic and enzymatic "active" sites would also lead to complete absence of enzyme activity. The problem is similar to that presented by other human mutations causing absence of gene product. A variety of genetic mechanisms including structural mutations can lead to the absence of a protein or enzyme. At our present state of knowledge, a definite conclusion regarding the specific nature of the mutation is not yet possible in such cases.
The mean pseudocholinesterase activity of five obligatory heterozygotes was 67%o of normal in our study and 717o of normal in six obligatory heterozygotes of Simpson and Kalow (8) . Similar observations were made by Harris and his coworkers (35) . It appears that the control of pseudocholinesterase activity, as that of other enzymes (36) , is exerted on the genic level and not by feedback repression (37) , so that individuals with only one mutant gene for pseudocholinesterase have less enzyme activity than normals. However, these individuals, unlike most heterozygotes in other systems, produce two-thirds, rather than one-half, of the enzyme activity of the normal homozygote.
Summary
Two sibs with complete absence of pseudocholinesterase activity were discovered in an American-Irish family. In both instances, prolonged apnea following succinylcholine administration was observed, but no other pathologic effect of the enzyme deficiency was apparent.
The family data were compatible with the hypothesis that "a pseudocholinesterasemia" represents the homozygous state for a gene that determines complete absence of pseudocholinesterase activity. Genetic considerations from this and previously reported families indicate that this gene is allelic with the two more frequently observed structural gene mutations affecting pseudocholinesterase.
Starch gel electrophoresis of serum from the index cases showed absence of the four isozyme bands associated with normal pseudocholinesterase activity. The electrophoretic pattern of these isozymes in subjects with the common structural ("dibucaine resistant") mutation of this enzyme was indistinguishable from normal. Heterozygotes for the rare "silent" allele had significantly less but more than half of normal cholinesterase activity.
Serum with complete absence of pseudocholinesterase activity failed to inhibit normal pseudocholinesterase activity.
Potential gene products in the sera with no enzyme activity were tested by immunologic methods. No cross-reacting or blocking material could be demonstrated by immunodiffusion and immunoelectrophoretic techniques. Although these findings would be expected with an operator type of mutation, certain structural mutations could lead to similar results.
